BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 20131015)

  • 1. Downstaging without complete pathologic response after neoadjuvant treatment improves cancer outcomes for cIII but not cII rectal cancers.
    de Campos-Lobato LF; Stocchi L; da Luz Moreira A; Kalady MF; Geisler D; Dietz D; Lavery IC; Remzi FH; Fazio VW
    Ann Surg Oncol; 2010 Jul; 17(7):1758-66. PubMed ID: 20131015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer.
    Tulchinsky H; Shmueli E; Figer A; Klausner JM; Rabau M
    Ann Surg Oncol; 2008 Oct; 15(10):2661-7. PubMed ID: 18389322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival.
    Cance WG; Carey LA; Calvo BF; Sartor C; Sawyer L; Moore DT; Rosenman J; Ollila DW; Graham M
    Ann Surg; 2002 Sep; 236(3):295-302; discussion 302-3. PubMed ID: 12192316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients.
    Bonnen M; Crane C; Vauthey JN; Skibber J; Delclos ME; Rodriguez-Bigas M; Hoff PM; Lin E; Eng C; Wong A; Janjan NA; Feig BW
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1098-105. PubMed ID: 15519780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.
    Chan AK; Wong A; Jenken D; Heine J; Buie D; Johnson D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):665-77. PubMed ID: 15708244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
    Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
    Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemoradiation versus hyperfractionated accelerated radiotherapy in locally advanced rectal cancer.
    Ceelen W; Boterberg T; Pattyn P; van Eijkeren M; Gillardin JM; Demetter P; Smeets P; Van Damme N; Monsaert E; Peeters M
    Ann Surg Oncol; 2007 Feb; 14(2):424-31. PubMed ID: 17096057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy?
    Kuo LJ; Liu MC; Jian JJ; Horng CF; Cheng TI; Chen CM; Fang WT; Chung YL
    Ann Surg Oncol; 2007 Oct; 14(10):2766-72. PubMed ID: 17551794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downstaging of T or N predicts long-term survival after preoperative chemotherapy and radical resection for esophageal carcinoma.
    Korst RJ; Kansler AL; Port JL; Lee PC; Kerem Y; Altorki NK
    Ann Thorac Surg; 2006 Aug; 82(2):480-4; discussion 484-5. PubMed ID: 16863749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer.
    Das P; Skibber JM; Rodriguez-Bigas MA; Feig BW; Chang GJ; Wolff RA; Eng C; Krishnan S; Janjan NA; Crane CH
    Cancer; 2007 May; 109(9):1750-5. PubMed ID: 17387743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermediate-fraction neoadjuvant radiotherapy for rectal cancer.
    Zhan T; Gu J; Li M; Du C
    Dis Colon Rectum; 2013 Apr; 56(4):422-32. PubMed ID: 23478609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy in stage III breast cancer.
    Alassas M; Chu Q; Burton G; Ampil F; Mizell J; Li BD
    Am Surg; 2005 Jun; 71(6):487-92. PubMed ID: 16044927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of clinical T4M0 extra-peritoneal rectal cancer treated with preoperative radiochemotherapy and surgery: a prospective evaluation of a single institutional experience.
    Valentini V; Coco C; Rizzo G; Manno A; Crucitti A; Mattana C; Ratto C; Verbo A; Vecchio FM; Barbaro B; Gambacorta MA; Montoro C; Barba MC; Sofo L; Papa V; Menghi R; D'Ugo DM; Doglietto G
    Surgery; 2009 May; 145(5):486-94. PubMed ID: 19375606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients.
    Capirci C; Valentini V; Cionini L; De Paoli A; Rodel C; Glynne-Jones R; Coco C; Romano M; Mantello G; Palazzi S; Mattia FO; Friso ML; Genovesi D; Vidali C; Gambacorta MA; Buffoli A; Lupattelli M; Favretto MS; La Torre G
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):99-107. PubMed ID: 18407433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
    Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
    Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?
    Mawdsley S; Glynne-Jones R; Grainger J; Richman P; Makris A; Harrison M; Ashford R; Harrison RA; Osborne M; Livingstone JI; MacDonald P; Mitchell IC; Meyrick-Thomas J; Northover JM; Windsor A; Novell R; Wallace M
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):745-52. PubMed ID: 16199310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of acellular mucin pools in resected rectal cancer with pathological complete response to neoadjuvant chemoradiation.
    de Campos-Lobato LF; Dietz DW; Stocchi L; Vogel JD; Lavery IC; Goldblum JR; Skacel M; Pelley RJ; Kalady MF
    Colorectal Dis; 2012 Jan; 14(1):62-7. PubMed ID: 21176057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.